Novel delivery methods for treatment of viral hepatitis: An update

Expert Opinion on Drug Delivery

Volumn 2, Issue 4, 2005, Pages 707-717

  Virovic, Lucija ^a   Wu, Catherine H ^a   Konishi, Masayoshi ^a   Wu, George Y ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Asialoglycoprotein receptors; Chronic viral hepatitis; Drug delivery; Hydrodynamic method; Liver; Viral vectors

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ACICLOVIR; ADEFOVIR; ALPHA INTERFERON; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; ARABINOGALACTAN; ASIALOGLYCOPROTEIN RECEPTOR; BETA INTERFERON; CYTARABINE; GAMMA INTERFERON; LAMIVUDINE; LEVOVIRIN; LIPOSOME; NANOPARTICLE; PEGINTERFERON; PULLULAN; RIBAMIDINE; RIBAVIRIN; SERUM ALBUMIN; SMALL INTERFERING RNA; VIDARABINE; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL PROTOCOL; CLINICAL TRIAL; DNA SYNTHESIS; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG TISSUE LEVEL; EXPRESSION VECTOR; GENE DELIVERY SYSTEM; HEPATITIS B; HEPATITIS C; HUMAN; NEUROTOXICITY; NONHUMAN; REVIEW; SIDE EFFECT; VIRUS HEPATITIS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; ASIALOGLYCOPROTEIN RECEPTOR; DRUG DELIVERY SYSTEMS; GENE THERAPY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIPOSOMES; NANOSTRUCTURES; POLYLYSINE; SERUM ALBUMIN; VEHICLES;

EID: 22844433703     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.4.707     Document Type: Review

References (71)

1. LAVANCHY D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral. Hepat. (2004) 11(3):97-107.
2. REISS G, KEEFFE EB: Review article: hepatitis vaccination in patients with chronic liver disease. Aliment. Pharmacol. Ther. (2004) 19(7):715-727.
3. YEN TSB: Regulation of hepatitis B virus gene expression. Semin Virol (1993) 4:33-42.
4. WRIGHT TL: Treatment for hepatitis B: the state of the art. In: Clinical Care Options for Hepatitis. JP Phair (Ed.), iMedOptions, Reston, VA, USA (2003):168.
5. LOK ASF: New treatment of chronic hepatitis B. Semin. Liv. Dis. (2004) 4(Suppl. 1):77-82.
6. BARTENSCHLAGER R, LOHMANN V: The hepatitis C virus. Baillieres Best Pract. Res. Clin. Gastroenterol. (2000) 14(2):241-254.
7. ROSENBERG S: Recent advances in the molecular biology of hepatitis C virus. J. Mol. Biol. (2002) 313:451-464.
8. NIH consensus statement on management of hepatitis C: 2002. NIH Consens. State Sci. Statements (2002) 19(3):1-46.
9. FOSTER GR: Past, present and future hepatitis C treatments. Semin. Liver Dis. (2004) 24(Suppl. 2):97-104.
10. ZEIN CO, ZEIN NN: Advances in therapy for hepatitis C infection. Microbes Infec. (2002) 4:1237-1246.
11. MCHUTCHISON JG, PATEL K: Future therapy of hepatitis C. Hepatology (2002) 36(5 Suppl. 1):S245-S252.
12. WU GY, WU CH: Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem. (1987) 262(10):4429-4432.
13. WU GY, WILSON JM, SHALABY F, GROSSMAN M, SHAFRITZ DA, WU CH: Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats. J. Biol. Chem. (1991) 266(22):14338-14342.
14. WU GY, ZHAN P, SZE LL, ROSENBERG AR, WU CH: Incorporation of adenovirus into a ligand-based DNA carrier system results in retention of original receptor specificity and enhances targeted gene expression. J. Biol. Chem. (1994) 269(15):11542-11546.
15. SCHUSTER MJ, WU GY, WALTON CM, WU CH: Multicomponent DNA carrier with a vesicular stomatitis virus G-peptide greatly enhances liver-targeted gene expression in mice. Bioconjug. Chem. (1999) 10(6):1075-1083.
16. WALTON CM, WU CH, WU GY: A DNA delivery system containing listeriolysin O results in enhanced hepatocyte-directed gene expression. World J. Gastroenterol. (1999) 5(6):465-469.
17. REINIS M, DAMKOVA M, KOREC E: Receptor-mediated transport of oligodeoxynucleotides into hepatic cells. J. Virol. Methods (1993) 42(1):99-105.
18. WU GY, WU CH: Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J. Biol. Chem. (1992) 267(18):12436-12439.
19. BARTHOLOMEW RM, CARMICHAEL EP, FINDEIS MA, WU CH, WU GY: Targeted delivery of antisense DNA in woodchuck hepatitis virus-infected woodchucks. J. Viral Hepat. (1995) 2(6):273-278.
20. WU CH, WU GY: Targeted inhibition of hepatitis C virus-directed gene expression in human hepatoma cell lines. Gastroenterology (1998) 114(6):1304-1312.
21. HOSTETLER KY, KORBA BE, SRIDHAR CN, GARDNER MF: Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B-infected cells and enhanced hepatic uptake in mice. Antiviral. Res. (1994) 24(1):59-67.
22. KORBA BA, XIE H, WRIGHT KN et al.: Liver-targeted antiviral nucleosides: enhanced antiviral activity of phosphatidyl-dideoxyguanosine versus dideoxyguanosine in woodchuck hepatitis virus infection in vivo. Hepatology (1996) 23(5):958-963.
23. BIJSTERBOSCH MK, VAN BERKEL TJ: Uptake of lactosylated low-density lipoprotein by galactose-specific receptors in rat liver. Biochem. J. (1990) 270(1):233-239.
24. BIJSTERBORSCH MK, VAN DE BILT H, VAN BERKEL TJ: Specific targeting of a lipophilic prodrug of iododeoxyuridine to parenchymal liver cells using lactosylated reconstituted high density lipoprotein particles. Biochem. Pharmacol. (1996) 52(1):113-121.
25. 1 to hepatocytes using galactosylated liposomes. J. Drug. Target. (2000) 8(3):137-142.
26. DE VRUEH RL, RUMP ET, VAN DE BILT E, et al.: Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B. Antimicrob. Agents. Chemother. (2000) 44(3):477-483.
27. BIJSTERBOSCH MK, YING C, DE VRUEH RL et al.: Carrier-mediated delivery improves the efficacy of 9-(2-phosphonylmethoxyethyl)adenine against hepatitis B virus. Mol. Pharmacol. (2001) 60(3):521-527.
28. BIESSEN EA, VALENTIJN AR, DE VRUEH RL et al.: Novel hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine with improved pharmacokinetics and antiviral activity. FASEB J. (2000) 14(12):1784-1792.
29. ISHIHARA H, HAYASHI Y, HARA T, ARAMAKI Y, TSUCHIYA S, KOIKE K: Specific uptake of asialofetuin-tacked liposomes encapsulating interferon-gamma by human hepatoma cells and its inhibitory effect on hepatitis B virus replication. Biochem. Biophys. Res. Commun. (1991) 174(2):839-845.
30. LAMBROS MP, ABBAS SA, DUNN ST, RAJA T, PENTO T: Targeting hepatocytes with liposomal interferon-alpha: effect on metallothionein gene induction. Res. Commun. Mol. Pathol. Pharmacol. (2002) 112(1-4):50-58.
31. BIJSTERBOSCH MK, MANOHARAN M, DORLAND R, VAN VEGHEL R, BIESSEN EA, VAN BERKEL TJ: Bis-cholesteryl-conjugated phosphorothioate oligodexynucleotides are highly selectively taken up by the liver. J. Pharmacol. Exp. Ther. (2002) 302(2):619-626.
32. LEHMANN TJ, ENGELS JW: Synthesis and properties of bile acid phosphoramidites 5′-tethered to antisense oligodeoxynucleotides against HCV. Bioorg. Med. Chem. (2001) 9(7):1827-1835.
33. FIUME L, MATTIOLI A, BUSI C, ACCORSI C: Selective penetration and pharmacological activity of lactosaminated albumin conjugates of adenine arabinoside 5-monophosphate (ara-AMP) in mouse liver. Gut (1984) 25(12):1392-1398.
34. FIUME L, BASSI B, BUSI C, MATTIOLI A, SPINOSA G: Drug targeting in antiviral chemotherapy. A chemically stable conjugate of 9-beta-D-arabinofuranosyl-adenine 5′-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells. Biochem. Pharmacol. (1986) 35(6):967-972.
35. FIUME L, BUSI C, DI STEFANO G et al.: Liver targeting of adenine arabinoside monophosphate (ara-AMP) by coupling to lactosaminated human serum albumin. Ital. J. Gastroenterol. (1995) 27(4):189-192.
36. PONZETTO A, FIUME L, FORZANI B et al.: Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viremia at doses lower than do the unconjugated drugs. Hepatology (1991) 14(1):16-24.
37. FIUME L, CERENZIA MR, BONINO F et al.: Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin. Lancet (1988) 2(8601):13-15.
38. TORRANI CERENZIA M, FIUME L, DE BERNARDI VENON W et al.: Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects. Hepatology (1996) 23(4):657-661.
39. WANG H, ZHANG L, WANG X: Preliminary clinic observation on the inhibiton of HBV by receptor-targeted drug L-HAS-AraAMP. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi (1998) 12(1):12-14.
40. FIUME L, DI STEFANO G, BUSI C, MATTIOLI A: A conjugate of lactosaminated poly-L-lysine with adenine arabinoside monophosphate, administered to mice by intramuscular route, accomplishes a selective delivery of the drug to the liver. Biochem. Pharmacol. (1994) 47(4):643-650.
41. DI STEFANO G, BUSI C, MATTIOLI A, FIUME L: Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-L-lysine and administered to mice by intramuscular route. Biochem. Pharmacol. (1995) 49(12):1769-1775.
42. FIUME L, DI STEFANO G, BUSI C, et al.: Inhibition of woodchuck hepatitis virus replication by adenine arabinoside monophosphate coupled to lactosaminated poly-L-lysine and administered by intramuscular route. Hepatology (1995) 22(4 Pt 1):1072-1077.
43. FIUME L, DI STEFANO G, BUSI C et al.: Hepatotropic conjugate of adenine arabinoside monophosphate with lactosaminated poly-L-lysine. Synthesis of the carrier and pharmacological properties of the conjugate. J. Hepatol. (1997) 26(2):253-259.
44. DI STEFANO G, COLONNA FP, BONGINI A, BUSI C, MATTIOLI A, FIUME L: Ribavirin conjugated with lactosaminated poly-L-lysine: selective delivery to the liver and increased antiviral activity in mice with viral hepatitis. Biochem. Pharmacol. (197) 54(3):357-363.
45. DI STEFANO G, BIGNAMINI A, BUSI C, COLONNA FP, FIUME L: Enhanced accumulation of ribavirin and its metabolites in liver versus erythrocytes in mice administered with the liver targeted drug. Ital. J. Gastroenterol. Hepatol. (1997) 29(5):420-426.
46. ZHONG S, WEN S, ZHANG D: Inhibition of HBV gene expression by antisense oligonucleotides using galactosylated poly(L-lysine) as a hepatotropic carrier. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi (2001) 15(2):150-153.
47. ENRIQUEZ PM, JUNG C, JOSEPHSON L, TENNANT BC: Conjugation of adenine arabinoside 5′-monophosphate to arabinogalactan: synthesis, characterization, and antiviral activity. Bioconjug. Chem. (1995) 6(2):195-202.
48. SUGINOSHITA Y, TABATA Y, MATSUMURA T et al.: Liver targeting of human interferon-beta with pullulan based on metal coordination. J. Control. Release (2002) 83(1):75-88.
49. JENSEN KD, KOPECKOVA P, KOPECEK J: Antisense oligonucleotides delivered to the lysosome escape and actively inhibit the hepatitis B virus. Bioconjug. Chem. (2002) 13(5):975-984.
50. DAVID A, KOPECKOVA P, RUBINSTEIN A, KOPECIK J: Enhanced biorecognition and internalization of HPMA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells. Bioconjugate Chem. (2001) 12:890-899.
51. AKAMATSU K, YAMASAKI Y, NISHIKAWA M, TAKAKURA Y, HASHIDA M: Synthesis and pharmacological activity of a novel water-soluble hepatocyte-specific polymeric prodrug of prostaglandin E(1) using lactosylated poly(L-glutamic hydrazide) as a carrier. Biochem. Pharmacol. (2001) 62(11):1531-1536.
52. TAKAHASHI H, ONISHI H, MACHIDA Y: Glycyrrhetic acid-loaded microparticles: liver-specific delivery and herapeutic potential against carbon tetrachloride-induced hepatitis. J. Pharm. Pharmacol. (2004) 56(4):437-444.
53. WELCH PJ, TRITZ R, YEI S, BARBER J, YU M: Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther. (1997) 4(7):736-743.
54. JI W, ST CW: Inhibition of hepatitis B virus by retroviral vectors expressing antisense RNA. J. Viral Hepat. (1997) 4(3):167-173.
55. SCAGLIONI P, MELEGARI M, TAKAHASHI M, CHOWDHURY JR, WANDS J: Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology (1996) 24(5):1010-1017.
56. ZHANG J, YAMADA O, SAKAMOTO T et al.: Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular cofactors for hepatitis C virus. Virology (2004) 320(1):135-143.
57. VANDENDRIESSCHE T, THORREY L, NALDINI L et al.: Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood (2002) 100(3):813-822.
58. CHUAH MK, SCHIEDNER G, THORREY L et al.: Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood (2003) 101(5):1734-1743.
59. ZHANG Z, HE Q: Study on liver targeted valaciclovir polybutylcyanoacrylate nanoparticles. Yao Xue Xue Bao (1998) 33(9):702-709.
60. FATTAL E, VAUTHIER C, AYNIE I et al.: Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. J. Control. Release (1998) 53(1-3):137-143.
61. SHIBUYA I, AKAIKE T, WATANABE Y: Design of a temporally and spatially controlled drug delivery system for the treatment of liver diseases in mice. Hepatology (2000) 32(6):1300-1308.
62. YAMADA T, IWASAKI Y, TADA H et al.: Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat. Biotechnol. (2003) 21(8):885-890.
63. ERION MD, VAN POELJE PD, MACKENNA DA et al.: Liver-targeted drug delivery using HepDirect Prodrugs. J. Pharm. Exp. Ther. (2005) 312(2):554-560.
64. BUDKER V, ZHANG G, KNECHTLE S, WOLFF JA: Naked DNA delivered intraportally expresses efficiently in hepatocytes. Gene Ther. (1996) 3(7):593-598.
65. ZHANG G, VARGO D, BUDKER V, ARMSTRONG N, KNECHTLE S, WOLFF JA: Expression of naked plasmid DNA injected into the afferent and efferent vessels of rodent and dog livers. Hum. Gene Ther. (1997) 8(15):1763-1772.
66. ZHANG G, BUDKER V, WOLFF JA: High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. (1999) 10(10):1735-1737.
67. MCCAFFREY AP, MEUSE L, PHAM TT, CONKLIN DS, HANNON GJ, KAY MA: RNA interference in adult mice. Nature (2002) 418(6893):38-39.
68. EASTMAN SJ, BASKIN KM, HODGES BL et al.: Development of catheter-based procedures for transducing the isolated rabbit liver with plasmid DNA. Hum. Gene Ther. (2002) 13(17):2065-2077.
69. ZHANG X, DONG X, SAWYER GJ, COLLINS L, FABRE JW: Regional hydrodynamic gene delivery to the rat liver with physiological volumes of DNA solution. J. Gene Med. (2004) 6(6):693-703.
70. YAMAGATA Y, IGA K, OGAWA Y: Novel sustained-release dosage forms of proteins using polyglycerol esters of fatty acids. J. Control. Release (2000) 63(3):319-329.
71. YAMAGATA Y, YUASA Y, YAMAMOTO K et al.: Pharmacologic effect of recombinant human IFN-alpha, continuously released from a matrix prepared from a polyglycerol ester of fatty acids, on 2′,5′-oligoadenylate synthetase activity in murine liver. J. Interferon Cytokine Res. (2000) 20(2):153-160.